Paul Brannelly joined Neurotech in July 2024 as the Company’s Chief Financial Officer.
Paul has 25 years of industry experience at public and private biotech companies, raising $1.5 billion in debt and equity.
Prior to joining Neurotech, he served as the chief financial officer of Ribon Therapeutics and Collegium Pharmaceutical. Additionally, Paul served in senior financial leadership roles at Karyopharm Therapeutics and Verastem.
Earlier in his career, he was the Chief Financial Officer of Longwood Fund, a healthcare dedicated venture capital fund, and held senior financial management roles with Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), CombinatoRx and Dyax.
Paul holds a bachelor’s in business administration in Accounting from the University of Massachusetts, Amherst and was a Certified Public Accountant.
,